


CRC for Inhibition of PARG Activity



Data shown are the mean % inhibition +/- SEM from all 14 tests

FIGURE 1

PAR IF n=3




FIGURE 2




FIGURE 3A




FIGURE 3B




FIGURE 4A





FIGURE 4B






FIGURE 4D




FIGURE 4E

HBC22x PDX Model




FIGURE 4F




FIGURE 4G

HBC34x PDX Model




FIGURE 4H




FIGURE 4I

RMUG-S CDX Study 1




Figure 5A




Figure 5B

RMUG-S CDX Study 2




Figure 5C




Figure 5D




Figure 5E




Figure 5F

T025OV HGSOC PDX Model




Figure 5G




Figure 5H

CRC for Inhibition of SNU601 Proliferation




FIGURE 6

OVCAR3 HGSOC




FIGURE 7

CRCs for Compound 1 in Combination with a Topoisomerase
I Inhibitor




FIGURE 8A




FIGURE 8B




FIGURE 8C

**CRCs for Inhibition of Proliferation of OCM.246 and OCM.109
Patient-Derived Organoids**




Figure 9

HCC1428 CDX Model




FIGURE 10A




FIGURE 10B

HCC1806 CDX Model




Figure 11A




Figure 11B